Irvington, N.Y., USA – MELA Sciences, Inc., a medical device company, appointed veteran healthcare executive Robert W. Cook as chief financial officer.[break]
Mr. Cook brings more than 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc., a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation.
Mr. Cook spent nine years as SVP and CFO at EpiCept where he was responsible for finance and accounting, SEC reporting, treasury, and budget, as well as IR/PR, information technology, facilities, human resources and corporate administration. He had previously served for six years as EVP and CFO of Pharmos Corporation, a publicly traded biopharmaceutical company.
Mr. Cook began his career in financial services, initially at The Chase Manhattan Bank, N.A. including several years as a managing director responsible for developing business in the U.S. pharmaceutical, medical device and hospital supply sectors. He subsequently served as a Vice President in the Healthcare Group at General Electric Capital Commercial Finance, focused on emerging life science companies.
M - April 10, 2014, Irvington, N.Y., USA – MELA Sciences, Inc., a medical device company, appointed veteran healthcare executive Robert W. Cook as chief financial officer.
Article continues below
]
Mr. Cook brings more than 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc., a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation.
Mr. Cook spent nine years as SVP and CFO at EpiCept where he was responsible for finance and accounting, SEC reporting, treasury, and budget, as well as IR/PR, information technology, facilities, human resources and corporate administration. He had previously served for six years as EVP and CFO of Pharmos Corporation, a publicly traded biopharmaceutical company.
Mr. Cook began his career in financial services, initially at The Chase Manhattan Bank, N.A. including several years as a managing director responsible for developing business in the U.S. pharmaceutical, medical device and hospital supply sectors. He subsequently served as a Vice President in the Healthcare Group at General Electric Capital Commercial Finance, focused on emerging life science companies. ■